Latest Content

Moderna’s mRNA flu vaccine receives FDA approval after phase 3 data showed improved efficacy compared with standard flu vaccines.

Health plans can use routine pharmacy claims to identify members at high risk for early discontinuation of glucagon-like peptide-1 receptor agonists and deliver targeted, equity-conscious adherence support.

CANN says the revised pilot reflects stakeholder input and aims to address accountability challenges in the more than $100 billion 340B program.

Higher CCI scores, prior infection, and prior prophylactic anti-infective treatment were associated with greater risk of subsequent infection in both cancers.

Lilly opens early access to retatrutide for some patients before FDA approval, following scrutiny over a single earlier compassionate-use case.

The former deputy surgeon general takes over an agency that has lacked permanent leadership since Susan Monarez, PhD, was ousted.

A review argues lung cancer screening should move beyond smoking history to include environmental exposures, family history, and AI-driven risk models.

Matched real-world MCL data shows acalabrutinib and zanubrutinib lower atrial fibrillation vs ibrutinib, with fewer bleeding events.

ORIGIN trial data suggest atacicept (Trutakna; Vera Therapeutics) is well tolerated in IgA nephropathy, with follow-up needed to assess long-term kidney outcomes.